BC
BLRX

Broadfin Capital’s BioLineRX BLRX Stock Holding History

Broadfin Capital’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,833
Closed -$4.55M – 78
2015
Q4 		$4.55M Hold
5,833
– – 0.28% 68
2015
Q3 		$5.36M Buy
5,833
+666
+13% +$711K 0.3% 67
2015
Q2 		$8.25M Hold
5,167
– – 0.44% 53
2015
Q1 		$6.54M Buy
+5,167
New +$6.36M 0.51% 51

Other funds holding BLRX

SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
MC
Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Broadfin Capital's BLRX Position: Q1 2016 in Review

Broadfin Capital sold out of BioLineRX (BLRX) in Q1 2016, closing a stake of 5,833 shares — an estimated $4.55M sold.

Broadfin Capital first reported a position in BLRX in Q1 2015 and held it in 4 quarters. The position peaked at $8.25M in Q2 2015. 26 funds tracked by Wall St. Rank hold BLRX as of Q1 2016.

  • Broadfin Capital reported no remaining BioLineRX position as of Q1 2016 after selling out during the quarter.
  • Broadfin Capital sold 5,833 BioLineRX shares in Q1 2016, an estimated $4.55M.
  • Broadfin Capital first reported a position in BioLineRX in Q1 2015 and held it in 4 quarters.
  • Broadfin Capital's BioLineRX position peaked at $8.25M in Q2 2015.
  • 26 funds tracked by Wall St. Rank held BioLineRX as of Q1 2016.

Based on Broadfin Capital's 13F filing for Q1 2016, filed 16 May 2016.